Hemoptisis Clinical Trial
Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that
varies from blood-streaking of sputum to coughing up large amounts of pure blood.
Massive hemoptysis variably defined as the expectoration of 100-600 ml over 24-h period.
The most common site of bleeding is the tracheobronchial tree, which can be affected by
inflammation (acute or chronic bronchitis, bronchiectasis) or by neoplasm ( bronchogenic
carcinoma, endobronchial metastatic carcinoma, bronchial carcinoid tumor). The bronchial
arteries, which originate either from aorta or from intercostal arteries, and are part of
the high-pressure systemic circulation, are the source of bleeding in bronchitis or
bronchiectasis or endo bronchial tumors.
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | February 2016 |
| Est. primary completion date | January 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 90 Years |
| Eligibility |
Inclusion Criteria: - Age > 18 - Hemodynamicaly stable - Hemoptysis of varying etiologies - Coumadin treatment will be switched to clexane or heparine Exclusion Criteria: - Age < 18 - Hemodinamicaly unstable - Massive hemoptysis ( > 200 ml / day) - Renal failure: creatinine > 3, renal replacement treatment - Hepatic failure: bilirubin > 2 mg/dl, AST > 3 of upper normal limit level - Coagulation disorders, INR> 2. - Hypesensitivity to tranexamic acid - Pregnant woman |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Israel | Pulmonary department, Meir Medical Center | Kfar Saba |
| Lead Sponsor | Collaborator |
|---|---|
| Meir Medical Center |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | bleeding stops | 1 year | No |